🔗 Share this article

As the United States undertakes historic revisions to its vaccination recommendations, a particular individual has surfaced unexpectedly: Høeg, a Danish American physician and epidemiologist who first made her name by questioning COVID-19 vaccines throughout the global health crisis and has zeroed in on possible fatalities after COVID-19 vaccination in her recent time at the Food and Drug Administration.

Scheduled Changes to Pediatric Vaccine Schedule

Health officials planned to reveal radical revisions to the pediatric vaccine schedule in December, synchronizing the US with Denmark’s national calendar, sources say – a significant shift that would put the US out of alignment with many the world with no evidence for benefit. This reveal has been postponed until the coming year.

In place of Vinay Prasad, Høeg is scheduled to speak at the event. She was recently named temporary leader of the FDA’s CDER, the fifth individual to head the center this year.

A New Direction at the FDA

The acting appointment could signify a strengthened alliance between the drug and vaccine branches as Høeg and Dr. Prasad solidify control at the FDA – and it suggests a increased emphasis upon dismantling previously authorized vaccines at the FDA.

Høeg has often pushed for halting certain childhood shot schedules in the US to become more like Denmark's approach, a society with comprehensive healthcare and a citizenry roughly the population of the state of Wisconsin.

In her initial public appearances, she has continued to focus on vaccines – typically the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Questions Over Background

The appointee has no apparent experience in medication creation, regulation or leadership, which has been customary for previous heads of the CBER. She has served at the FDA as a top consultant to the commissioner and the vaccine center since March.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, said Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in managing a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former heads of the center would “be deeply familiar with regulatory frameworks and the underlying principles of drug development”, commented a former acting FDA commissioner. “Objectively, she has not acquired the kind of background that former directors who ran the center have had.”

The drug center has an enormous portfolio at the agency, she stated.

“Everybody just focuses on the new drug program, but the generic drug division authorizes thousands of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and so forth, and all of those have to be looked after,” Dr. Woodcock noted. “The area you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a major management element to the job, which manages over 5,000 staff members. “It is a massive management job, if you perform it correctly,” she added.

Agency Reaction and Disputed Policies

When asked about questions about Høeg’s qualifications and whether this appointment represents increased cooperation among FDA leaders on vaccines, a representative said that the “concerns are based on flawed assumptions”.

“Her experience matches the duties of her role,” the spokesperson said, citing the period Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg takes over the agency head's recently launched expedited review system, a disputed one-day medication authorization process that allegedly worried her former heads. “How are these medications being picked for this voucher program? Who takes the calls?” Dr. Howard said. “There’s a lot of lack of transparency happening at the agency right now.”

In general, he remarked, “the agency appears to be shifting towards more relaxed regulations of all drugs, aside from shots.”

Established Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a clearer, if concerning, past, some experts said. She authored a research paper using unconfirmed public submissions to assess the rate of myocarditis after COVID-19 vaccination. She consulted for the Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the current government included revising guidelines for recently developed shots and discontinuing “unnecessary” vaccines, she stated after the election on a podcast. At the FDA, Høeg has according to sources suggested barring young men from receiving COVID-19 vaccines.

“She’s an thorough dogmatist who starts off with her beliefs and tailors the evidence to accommodate the data in a very disingenuous, dishonest manner,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of fellow dissenters, {like|